MetaCap

GT Biopharma (GTBP) vs Kyntra Bio (KYNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GT Biopharma (GTBP) has outperformed Kyntra Bio (KYNB) over the past year, gaining 303.3% versus a loss of 81.5%. Over five years, GTBP leads with a -97.8% price change compared with -99.5% for KYNB. GT Biopharma is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GTBP+303.27%KYNB-81.47%
+1563%+701%-160%
Nov 21, 20251 yearNov 20, 2026
GTBP-98.02%KYNB-99.49%
+111%+1%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GTBP versus KYNB key metrics
MetricGTBPKYNB
Share price$2.96$1.56
Market cap$6.33M$6.32M
1-day change-6.92%-13.33%
YTD return+277.07%-82.23%
1-year return+303.27%-81.47%
5-year return-97.77%-99.49%
EPS (TTM)$-128.61$-4.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.44M
Revenue growth (YoY)—-78.26%
Net income (latest FY)$-28.35M$183.45M
Gross margin—91.37%
Operating margin—-712.66%
Net margin—2848.63%
52-week high$23.60$10.47
52-week low$2.87$1.56
Distance from 52-week high-87.46%-85.10%
Analyst consensusnonenone
Avg. price target upside+2433.78%+2442.95%
Average volume78.16K29.96K
Shares outstanding2.14M4.05M
Employees134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GTBP has outperformed KYNB by 384.7 percentage points over the past year.

About GT Biopharma

GTBP stock →

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

About Kyntra Bio

KYNB stock →

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

GTBP vs KYNB FAQ

Which is bigger, GT Biopharma or Kyntra Bio?

GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $6.32M for Kyntra Bio (KYNB).

Which stock has performed better over the past year, GTBP or KYNB?

GTBP returned +303.27% over the past 12 months, compared with -81.47% for KYNB (price return, excluding dividends). Past performance does not predict future results.

Are GT Biopharma and Kyntra Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons